LYELL IMMUNOPHARMA
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
LYELL IMMUNOPHARMA
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2018-01-01
Status:
Active
Contact:
1 650-695-0677
Total Funding:
493 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Mobile Non Scaleable Content Nginx Amazon IPv6
Similar Organizations
Adyn
Adyn is a precision medicine company that develops personalized birth control methods.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Cerespir
Cerespir is an operator of a biotechnology company intended to treat neurodegenerative disorders.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
ESSA Pharma
ESSA Pharma is a biotechnology company that develops new drugs for prostate cancer.
Instil Bio
Instil Bio is a biotechnology company that develops cell therapies for solid tumor cures.
Kallyope
Kallyope is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis.
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Olema Oncology
Olema Oncology is a preclinical biotechnology company that develops new drugs for the treatment and prevention of breast cancer.
Outpace Bio
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.
PanTheryx
PanTheryx is a nutrition and biotechnology company that utilizes the cellular and biomolecular processes of bovine colostrum.
PocketPills
Pocketpills is an online pharmacy that provides medication and refill transfers.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
The Public Health Company
The Public Health Company is a biotechnology firm that offers a platform for genomic epidemiology scientists to outbreak intelligence.
Toregem BioPharma
Toregem BioPharma is a startup from Kyoto University that develops a treatment for congenital adentia.
Triumvira Immunologics
Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Employees Featured
Elizabeth Homans CEO @ Lyell Immunopharma
CEO
2020-01-01
Scott Boyken Co-Founder, Co-Director of Protein & Cell Engineering @ Lyell Immunopharma
Co-Founder, Co-Director of Protein & Cell Engineering
Heather Turner Chief Legal Officer @ Lyell Immunopharma
Chief Legal Officer
2019-04-01
Gary Lee Chief Scientific Officer @ Lyell Immunopharma
Chief Scientific Officer
2022-01-01
Omar Ali Senior Director of Research @ Lyell Immunopharma
Senior Director of Research
2020-05-01
Hector Casab VP Finance @ Lyell Immunopharma
VP Finance
2021-03-01
Founder
Stock Details
Investors List
Sahsen Ventures
Sahsen Ventures investment in Series A - Lyell Immunopharma
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Series A - Lyell Immunopharma
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Lyell Immunopharma
Arrive
Arrive investment in Series A - Lyell Immunopharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-03-31 | Outpace Bio | Lyell Immunopharma investment in Series A - Outpace Bio | 30 M USD |
| 2020-09-30 | Sonoma Pharmaceuticals | Lyell Immunopharma investment in Post-IPO Equity - Sonoma Pharmaceuticals | 70 M USD |
| 2020-09-30 | Sonoma BioTherapeutics | Lyell Immunopharma investment in Series A - Sonoma BioTherapeutics | 30 M USD |
| 2020-03-18 | Cero Therapeutics | Lyell Immunopharma investment in Series A - Cero Therapeutics | 40 M USD |
| 2020-03-17 | Eureka Therapeutics | Lyell Immunopharma investment in Series E - Eureka Therapeutics | 45 M USD |
| 2020-02-06 | Sonoma BioTherapeutics | Lyell Immunopharma investment in Series A - Sonoma BioTherapeutics | 40 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-31 | Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer |
More informations about "Lyell Immunopharma"
Our Team - Lyell
Stephen Hill has served as our Chief Operating Officer since October 2021. He joined Lyell in June 2019 as our Chief Technical Operations Officer. From June 2018 to June 2019, he was …See details»
Lyell Immunopharma - Crunchbase Investor Profile
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes …See details»
Our Story | Lyell
Lyell is a clinical-stage cell therapy company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. ... LyFE Manufacturing …See details»
Cellares and Lyell to Evaluate Automated …
Sep 11, 2023 SOUTH SAN FRANCISCO, September 11, 2023 – Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Lyell …See details»
Lyell Immunopharma - Funding, Financials, Valuation & Investors
Lyell Immunopharma is registered under the ticker NASDAQ:LYEL . Their stock opened with $17.00 in its Jun 16, 2021 IPO. Lyell Immunopharma is funded by 5 investors. Sahsen …See details»
Lyell Immunopharma, Inc. - Drug pipelines, Patents, Clinical
Explore Lyell Immunopharma, Inc. with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, 166 news, and 14 literature, Disease Domain:Neoplasms, Immune System …See details»
Lyell Company Profile - Office Locations, Competitors, Revenue
Oct 29, 2024 Lyell has 1 employees across 3 locations and $61 k in annual revenue in FY 2024. See insights on Lyell including office locations, competitors, revenue, financials, executives, …See details»
Lyell loses 25% of staff, CMO to conserve cash post …
Nov 8, 2023 A year after Lyell Immunopharma lost a $1 billion biobucks partnership with GSK, the cell therapy biotech is offloading a quarter of its staff and deprioritizing some earlier-stage research to ...See details»
Lyell to Highlight Vision for its Next-Generation CAR T-Cell …
Jan 9, 2025 Lyell Immunopharma, Inc . Thu, Jan 9, 2025, 9:00 AM 10 ... we have streamlined and focused our pipeline and organization to prioritize investment in IMPT-314 and early-stage …See details»
Lyell Immunopharma Announces Participation in Upcoming …
Feb 18, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next …See details»
Lyell to Highlight Vision for its Next-Generation CAR T-Cell …
Jan 9, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next …See details»
Lyell Immunopharma Inc Company Profile - Overview - GlobalData
Lyell Immunopharma Inc (Lyell) is a biotechnology company developing cell-based immunotherapies for solid tumors and other cancers. The company's pipeline products include …See details»
Lyell, in search of a turnaround, to buy cell therapy startup ImmPact
Oct 24, 2024 Lyell Immunopharma, a cell therapy developer that has struggled to match its high profile, is acquiring a biotechnology startup and streamlining research in a bid to focus on a …See details»
Our Pipeline - Lyell
Lyell, Epi-R, Stim-R, LyFE Manufacturing Center and the Lyell logo are trademarks owned by Lyell Immunopharma, Inc. About Us Our Story Our Team. Our Science Our Technology …See details»
Lyell Immunopharma Accelerates Development of IMPT-314 for
Jan 9, 2025 Lyell Immunopharma, Inc. has announced plans to accelerate the development of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell …See details»
GSK and Lyell Immunopharma join forces to develop the next …
Oct 8, 2019 Dr. Rick Klausner, founder and CEO, Lyell Immunopharma said: “Our approach is to tackle three of the most significant barriers to T cell efficacy in solid tumours. We are …See details»
Lyell Immunopharma Director Acquires 35,640 Shares
2 days ago Otis W Brawley, a Director at Lyell Immunopharma, purchased 35,640 shares of the company's common stock on March 31, 2025. The shares were bought at a price of $0.56 per …See details»
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its …
Oct 25, 2024 SOUTH SAN FRANCISCO, CA, USA I October 24, 2024 I Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced today that it has entered into a definitive agreement to …See details»
Lyell Immunopharma Inc - Cerrará el centro de fabricación de …
3 days ago Lyell Immunopharma, Inc. presenta los resultados del cuarto trimestre y del año completo finalizado el 31 de diciembre de 2024 11/03: CI Lyell Immunopharma, Inc. Presents …See details»
Il titolo di Lyell Immunopharma tocca il minimo di 52 settimane a …
2 days ago Lyell Immunopharma ha anche mantenuto le sue previsioni finanziarie per il 2025, proiettando un utilizzo netto di liquidità tra $175 milioni e $185 milioni, estendendo la sua …See details»